Waldenström macroglobulinemia: my way

References

• Kyle RA, Dispenzieri A, Kumar S, . IgM monoclonal gammopathy of undetermined significance (MGUS) and smoldering Waldenstrom's macroglobulinemia (SWM). Clin Lymphoma Myeloma Leuk 2011;11:74–76.
   PubMed Web of Science ®Google Scholar
• Rajkumar SV, Kyle RA, Buadi FK. Advances in the diagnosis, classification, risk stratification, and management of monoclonal gammopathy of undetermined significance: implications for recategorizing disease entities in the presence of evolving scientific evidence. Mayo Clin Proc 2010;85:945–948.
   PubMed Web of Science ®Google Scholar
• Landgren O, Kyle RA, Rajkumar SV. From myeloma precursor disease to multiple myeloma: new diagnostic concepts and opportunities for early intervention. Clin Cancer Res 2011;17:1243–1252.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Benson J, Larson D, . IgM monoclonal gammopathy of undetermined significance and smoldering Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma 2009;9:17–18.
   PubMedGoogle Scholar
• Wang H, Chen Y, Li F, . Temporal and geographic variations of Waldenstrom macroglobulinemia incidence: a large population-based study. Cancer 2012;118:3793–3800.
   PubMed Web of Science ®Google Scholar
• Greenberg AJ, Vachon CM, Rajkumar SV. Disparities in the prevalence, pathogenesis and progression of monoclonal gammopathy of undetermined significance and multiple myeloma between blacks and whites. Leukemia 2012;26:609–614.
   PubMed Web of Science ®Google Scholar
• Landgren O, Katzmann JA, Hsing AW, . Prevalence of monoclonal gammopathy of undetermined significance among men in Ghana. Mayo Clin Proc 2007;82:1468–1473.
   PubMed Web of Science ®Google Scholar
• Owen RG, Treon SP, Al-Katib A, . Clinicopathological definition of Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003;30:110–115.
   PubMed Web of Science ®Google Scholar
• Iida S, Rao PH, Ueda R, . Chromosomal rearrangement of the PAX-5 locus in lymphoplasmacytic lymphoma with t(9;14)(p13;q32). Leuk Lymphoma 1999;34:25–33.
   PubMed Web of Science ®Google Scholar
• Ackroyd S, O’Connor SJ, Owen RG. Rarity of IgH translocations in Waldenstrom macroglobulinemia. Cancer Genet Cytogenet 2005;163:77–80.
   PubMed Web of Science ®Google Scholar
• Du MQ. MALT lymphoma: recent advances in aetiology and molecular genetics. J Clin Exp Hematopathol 2007;47:31–42.
   PubMedGoogle Scholar
• Sander B. Mantle cell lymphoma: recent insights into pathogenesis, clinical variability, and new diagnostic markers. Semin Diagn Pathol 2011;28:245–255.
   PubMed Web of Science ®Google Scholar
• Panayiotidis P, Kotsi P. Genetics of small lymphocyte disorders. Semin Hematol 1999;36:171–177.
   PubMed Web of Science ®Google Scholar
• Janssens A, Van Roy N, Poppe B, . High-risk clonal evolution in chronic B-lymphocytic leukemia: single-center interphase fluorescence in situ hybridization study and review of the literature. Eur J Haematol 2012;89:72–80.
   PubMed Web of Science ®Google Scholar
• Freedman A. Follicular lymphoma: 2011 update on diagnosis and management. Am J Hematol 2011;86:768–775.
   PubMed Web of Science ®Google Scholar
• Chang H, Qi C, Trieu Y, . Prognostic relevance of 6q deletion in Waldenstrom's macroglobulinemia: a multicenter study. Clin Lymphoma Myeloma 2009;9:36–38.
   PubMedGoogle Scholar
• Ngo VN, Young RM, Schmitz R, . Oncogenically active MYD88 mutations in human lymphoma. Nature 2011;470:115–119.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Treon SP, Alexanian R, . Prognostic markers and criteria to initiate therapy in Waldenstrom's macroglobulinemia: consensus panel recommendations from the Second International Workshop on Waldenstrom's Macroglobulinemia. Semin Oncol 2003; 30:116–120.
   PubMed Web of Science ®Google Scholar
• Stone MJ. Pathogenesis and morbidity of autoantibody syndromes in Waldenstrom's macroglobulinemia. Clin Lymphoma Myeloma Leuk 2011;11:157–159.
   PubMed Web of Science ®Google Scholar
• Tedeschi A, Barate C, Minola E, . Cryoglobulinemia. Blood Rev 2007;21:183–200.
   PubMed Web of Science ®Google Scholar
• Lunn MP, Nobile-Orazio E. Immunotherapy for IgM anti-myelin-associated glycoprotein paraprotein-associated peripheral neuropathies. Cochrane Database Syst Rev 2012;(5):CD002827.
   Google Scholar
• Gertz MA, Buadi FK, Hayman SR. IgM amyloidosis: clinical features in therapeutic outcomes. Clin Lymphoma Myeloma Leuk 2011;11:146–148.
   PubMed Web of Science ®Google Scholar
• Merlini G, Stone MJ. Dangerous small B-cell clones. Blood 2006;108:2520–2530.
   PubMed Web of Science ®Google Scholar
• Kastritis E, Kyrtsonis MC, Hatjiharissi E, . No significant improvement in the outcome of patients with Waldenstrom's macroglobulinemia treated over the last 25 years. Am J Hematol 2011;86:479–483.
   PubMed Web of Science ®Google Scholar
• Ricci F, Tedeschi A, Vismara E, . The impact of advanced age according to IPSSWM cut-off on the outcome of symptomatic and asymptomatic Waldenstrom's macroglobulinemia at diagnosis. Clin Lymphoma Myeloma Leuk 2011;11:124–126.
   PubMed Web of Science ®Google Scholar
• Merchionne F, Procaccio P, Dammacco F. Waldenstrom's macroglobulinemia. An overview of its clinical, biochemical, immunological and therapeutic features and our series of 121 patients collected in a single center. Crit Rev Oncol Hematol 2011;80:87–99.
   Google Scholar
• Kastritis E, Zervas K, Repoussis P, . Prognostication in young and old patients with Waldenstrom's macroglobulinemia: importance of the International Prognostic Scoring System and of serum lactate dehydrogenase. Clin Lymphoma Myeloma 2009;9:50–52.
   PubMedGoogle Scholar
• Kimby E, Treon SP, Anagnostopoulos A, . Update on recommendations for assessing response from the Third International Workshop on Waldenstrom's Macroglobulinemia. Clin Lymphoma Myeloma 2006;6:380–383.
   PubMedGoogle Scholar
• Del Giudice I, Matutes E, Osuji N, . Delayed response to fludarabine in lymphoplasmacytic lymphoma/Waldenstrom's macroglobulinemia. Haematologica 2005;90:268–270.
   PubMedGoogle Scholar
• Dhodapkar MV, Hoering A, Gertz MA, . Long-term survival in Waldenstrom macroglobulinemia: 10-year follow-up of Southwest Oncology Group-directed intergroup trial S9003. Blood 2009;113: 793–796.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Abonour R, Heffner LT, . Clinical value of minor responses after 4 doses of rituximab in Waldenstrom macroglobulinaemia: a follow-up of the Eastern Cooperative Oncology Group E3A98 trial. Br J Haematol 2009;147:677–680.
   PubMed Web of Science ®Google Scholar
• Izzedine H, Bourry E, Amrouche L, . Immunoglobulin M “flare” after rituximab-associated acute tubular necrosis in Waldenstrom's macroglobulinemia. Int J Hematol 2009;89:218–222.
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Fonseca R, Greipp PR, . Initial immunoglobulin M “flare” after rituximab therapy in patients diagnosed with Waldenstrom macroglobulinemia: an Eastern Cooperative Oncology Group Study. Cancer 2004;101:2593–2598.
   PubMed Web of Science ®Google Scholar
• Treon SP, Branagan AR, Hunter Z, . Paradoxical increases in serum IgM and viscosity levels following rituximab in Waldenstrom's macroglobulinemia. Ann Oncol 2004;15:1481–1483.
   PubMed Web of Science ®Google Scholar
• Morel P, Duhamel A, Gobbi P, . International prognostic scoring system for Waldenstrom macroglobulinemia. Blood 2009; 113:4163–4170.
   PubMed Web of Science ®Google Scholar
• Kastritis E, Kyrtsonis MC, Hadjiharissi E, . Validation of the International Prognostic Scoring System (IPSS) for Waldenstrom's macroglobulinemia (WM) and the importance of serum lactate dehydrogenase (LDH). Leuk Res 2010;34:1340–1343.
   PubMed Web of Science ®Google Scholar
• Kyle RA, Greipp PR, Gertz MA, . Waldenstrom's macroglobulinaemia: a prospective study comparing daily with intermittent oral chlorambucil. Br J Haematol 2000;108:737–742.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Panayiotidis P, Moulopoulos LA, . Waldenstrom's macroglobulinemia: clinical features, complications, and management. J Clin Oncol 2000;18:214–226.
   PubMed Web of Science ®Google Scholar
• Facon T, Brouillard M, Duhamel A, . Prognostic factors in Waldenstrom's macroglobulinemia: a report of 167 cases. J Clin Oncol 1993;11:1553–1558.
   PubMed Web of Science ®Google Scholar
• Petrucci MT, Avvisati G, Tribalto M, . Waldenstrom's macroglobulinaemia: results of a combined oral treatment in 34 newly diagnosed patients. J Intern Med 1989;226:443–447.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Rue M, Blood E, . Multicenter phase 2 trial of rituximab for Waldenstrom macroglobulinemia (WM): an Eastern Cooperative Oncology Group Study (E3A98). Leuk Lymphoma 2004;45:2047–2055.
   PubMed Web of Science ®Google Scholar
• Dimopoulos MA, Anagnostopoulos A, Kyrtsonis MC, . Primary treatment of Waldenstrom macroglobulinemia with dexamethasone, rituximab, and cyclophosphamide. J Clin Oncol 2007;25:3344–3349.
   PubMed Web of Science ®Google Scholar
• Treon SP, Branagan AR, Ioakimidis L, . Long-term outcomes to fludarabine and rituximab in Waldenstrom macroglobulinemia. Blood 2009;113:3673–3678.
   PubMed Web of Science ®Google Scholar
• Laszlo D, Andreola G, Rigacci L, . Rituximab and subcutaneous 2-chloro-2’-deoxyadenosine combination treatment for patients with Waldenstrom macroglobulinemia: clinical and biologic results of a phase II multicenter study. J Clin Oncol 2010;28:2233–2238.
   PubMed Web of Science ®Google Scholar
• Tedeschi A, Benevolo G, Varettoni M, . Fludarabine plus cyclophosphamide and rituximab in Waldenstrom macroglobulinemia: an effective but myelosuppressive regimen to be offered to patients with advanced disease. Cancer 2012;118:434–443.
   PubMed Web of Science ®Google Scholar
• Treon SP, Soumerai JD, Branagan AR, . Thalidomide and rituximab in Waldenstrom macroglobulinemia. Blood 2008;112: 4452–4457.
   PubMed Web of Science ®Google Scholar
• Treon SP, Soumerai JD, Branagan AR, . Lenalidomide and rituximab in Waldenstrom's macroglobulinemia. Clin Cancer Res 2009;15:355–360.
   PubMed Web of Science ®Google Scholar
• Nobile-Orazio E. IgM paraproteinaemic neuropathies. Curr Opin Neurol 2004;17:599–605.
   PubMed Web of Science ®Google Scholar
• Chen CI, Kouroukis CT, White D, . Bortezomib is active in patients with untreated or relapsed Waldenstrom's macroglobulinemia: a phase II study of the National Cancer Institute of Canada Clinical Trials Group. J Clin Oncol 2007;25:1570–1575.
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Hong F, Padmanabhan S, . Phase II trial of weekly bortezomib in combination with rituximab in relapsed or relapsed and refractory Waldenstrom macroglobulinemia. J Clin Oncol 2010;28:1422–1428.
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Xie W, Padmanabhan S, . Phase II trial of weekly bortezomib in combination with rituximab in untreated patients with Waldenstrom macroglobulinemia. Am J Hematol 2010;85:670–674.
   PubMed Web of Science ®Google Scholar
• Agathocleous A, Rohatiner A, Rule S, . Weekly versus twice weekly bortezomib given in conjunction with rituximab, in patients with recurrent follicular lymphoma, mantle cell lymphoma and Waldenstrom macroglobulinaemia. Br J Haematol 2010;151: 346–353.
   PubMed Web of Science ®Google Scholar
• Ghobrial IM, Gertz M, Laplant B, . Phase II trial of the oral mammalian target of rapamycin inhibitor everolimus in relapsed or refractory Waldenstrom macroglobulinemia. J Clin Oncol 2010;28: 1408–1414.
   PubMed Web of Science ®Google Scholar
• Gertz MA, Reeder CB, Kyle RA, . Stem cell transplant for Waldenstrom macroglobulinemia: an underutilized technique. Bone Marrow Transplant 2011 Aug 29. [Epub ahead of print]
   Web of Science ®Google Scholar
• Kyriakou C, Canals C, Sibon D, . High-dose therapy and autologous stem-cell transplantation in Waldenstrom macroglobulinemia: the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2010; 28:2227–2232.
   PubMed Web of Science ®Google Scholar
• Kyriakou C, Canals C, Cornelissen JJ, . Allogeneic stem-cell transplantation in patients with Waldenstrom macroglobulinemia: report from the Lymphoma Working Party of the European Group for Blood and Marrow Transplantation. J Clin Oncol 2010;28:4926–4934.
   PubMed Web of Science ®Google Scholar
• Rummel MJ, Niederle N, von Grunhagen U. Bendamustine plus rituximab versus CHOP plus rituximab as first-line-treatment in patients with indolent lymphomas and Waldenström's macroglobulinemia. Abstract presented at The Sixth International Workshop on Waldenström's Macroglobulinemia. 6–10 October 2010. Venice, Italy.
   Google Scholar
• Ansell SM, Kyle RA, Reeder CB, . Diagnosis and management of Waldenstrom macroglobulinemia: Mayo stratification of macroglobulinemia and risk-adapted therapy (mSMART) guidelines. Mayo Clin Proc 2010;85:824–833.
   PubMed Web of Science ®Google Scholar
• Stone MJ, Bogen SA. Evidence-based focused review of management of hyperviscosity syndrome. Blood 2012;119:2205–2208.
   PubMed Web of Science ®Google Scholar
• Mikhael JR, Schuster SR, Jimenez-Zepeda VH, . Cyclophosphamide-bortezomib-dexamethasone (CyBorD) produces rapid and complete hematologic response in patients with AL amyloidosis. Blood 2012;119:4391–4394.
   PubMed Web of Science ®Google Scholar
• Khan ML, Reeder CB, Kumar SK, . A comparison of lenalidomide/dexamethasone versus cyclophosphamide/lenalidomide/ dexamethasone versus cyclophosphamide/bortezomib/dexamethasone in newly diagnosed multiple myeloma. Br J Haematol 2012;156: 326–333.
   PubMed Web of Science ®Google Scholar
• Reeder CB, Reece DE, Kukreti V, . Once- versus twice-weekly bortezomib induction therapy with CyBorD in newly diagnosed multiple myeloma. Blood 2010;115:3416–3417.
   PubMed Web of Science ®Google Scholar